📣 VC round data is live. Check it out!
- Public Comps
- BRAIN Biotech
BRAIN Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for BRAIN Biotech and similar public comparables like eXoZymes, Exel Composites, DGL Group, I-Tech and more.
BRAIN Biotech Overview
About BRAIN Biotech
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
Founded
1993
HQ

Employees
281
Website
Sectors
Financials (LTM)
EV
$86M
Valuation Multiples
Start free trialBRAIN Biotech Financials
BRAIN Biotech reported last 12-month revenue of $65M and EBITDA of $530K.
In the same LTM period, BRAIN Biotech generated $530K in EBITDA and had net loss of ($9M).
Revenue (LTM)
BRAIN Biotech P&L
In the most recent fiscal year, BRAIN Biotech reported revenue of $62M and EBITDA of ($830K).
BRAIN Biotech is unprofitable as of last fiscal year, with gross margin of 54%, EBITDA margin of (1%), and net margin of (18%).
Financial data powered by Morningstar, Inc.
BRAIN Biotech Stock Performance
BRAIN Biotech has current market cap of $83M, and enterprise value of $86M.
Market Cap Evolution
BRAIN Biotech's stock price is $3.81.
BRAIN Biotech share price increased by 18.2% in the last 30 days, and by 57.3% in the last year.
BRAIN Biotech has an EPS (earnings per share) of $-0.50.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $86M | $83M | 2.4% | 18.2% | 27.1% | 57.3% | $-0.50 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBRAIN Biotech Valuation Multiples
BRAIN Biotech trades at 1.3x EV/Revenue multiple, and 161.9x EV/EBITDA.
EV / Revenue (LTM)
BRAIN Biotech Financial Valuation Multiples
As of May 9, 2026, BRAIN Biotech has market cap of $83M and EV of $86M.
BRAIN Biotech has a P/E ratio of (8.8x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BRAIN Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


BRAIN Biotech Margins & Growth Rates
BRAIN Biotech grew revenue by 8% but EBITDA decreased by 271% in the last fiscal year.
In the most recent fiscal year, BRAIN Biotech reported gross margin of 54%, EBITDA margin of (1%), and net margin of (18%).
BRAIN Biotech Margins
BRAIN Biotech Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
BRAIN Biotech Operational KPIs
BRAIN Biotech's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
BRAIN Biotech's Rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BRAIN Biotech's Rule of X is 41% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
BRAIN Biotech Competitors
BRAIN Biotech competitors include eXoZymes, Exel Composites, DGL Group, I-Tech, Amoeba, American Vanguard, IBU-tec adv materials, Baikowski, Holland and Northern Technologies.
Most BRAIN Biotech public comparables operate across Chemicals.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| — | — | (8.5x) | — | |||
| 0.9x | 0.9x | 13.2x | 10.2x | |||
| 0.6x | 0.6x | 5.5x | 5.5x | |||
| 4.1x | 3.9x | 14.1x | 13.2x | |||
| — | 46.6x | (13.0x) | (15.4x) | |||
| 0.6x | 0.6x | (25.4x) | 7.6x | |||
| 1.6x | 2.0x | 81.3x | 21.2x | |||
| 1.7x | — | 9.8x | — | |||
This data is available for Pro users. Sign up to see all BRAIN Biotech competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BRAIN Biotech
| When was BRAIN Biotech founded? | BRAIN Biotech was founded in 1993. |
| Where is BRAIN Biotech headquartered? | BRAIN Biotech is headquartered in Germany. |
| How many employees does BRAIN Biotech have? | As of today, BRAIN Biotech has over 281 employees. |
| Is BRAIN Biotech publicly listed? | Yes, BRAIN Biotech is a public company listed on Frankfurt Stock Exchange. |
| What is the stock symbol of BRAIN Biotech? | BRAIN Biotech trades under BNN ticker. |
| When did BRAIN Biotech go public? | BRAIN Biotech went public in 2016. |
| Who are competitors of BRAIN Biotech? | BRAIN Biotech main competitors include eXoZymes, Exel Composites, DGL Group, I-Tech, Amoeba, American Vanguard, IBU-tec adv materials, Baikowski, Holland, Northern Technologies. |
| What is the current market cap of BRAIN Biotech? | BRAIN Biotech's current market cap is $83M. |
| What is the current revenue of BRAIN Biotech? | BRAIN Biotech's last 12 months revenue is $65M. |
| What is the current revenue growth of BRAIN Biotech? | BRAIN Biotech revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of BRAIN Biotech? | Current revenue multiple of BRAIN Biotech is 1.3x. |
| Is BRAIN Biotech profitable? | Yes, BRAIN Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BRAIN Biotech? | BRAIN Biotech's last 12 months EBITDA is $530K. |
| What is BRAIN Biotech's EBITDA margin? | BRAIN Biotech's last 12 months EBITDA margin is 1%. |
| What is the current EV/EBITDA multiple of BRAIN Biotech? | Current EBITDA multiple of BRAIN Biotech is 161.9x. |
| What is the current FCF of BRAIN Biotech? | BRAIN Biotech's last 12 months FCF is ($5M). |
| What is BRAIN Biotech's FCF margin? | BRAIN Biotech's last 12 months FCF margin is (7%). |
| What is the current EV/FCF multiple of BRAIN Biotech? | Current FCF multiple of BRAIN Biotech is (18.4x). |
| How many companies BRAIN Biotech has acquired to date? | BRAIN Biotech hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies BRAIN Biotech has invested to date? | BRAIN Biotech hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to BRAIN Biotech
Lists including BRAIN Biotech
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.